Drug Type Monoclonal antibody |
Synonyms MONOCLONAL ANTIBODY 3F8, 3F8 MAB, 3F8-MAB + [3] |
Target |
Action inhibitors, stimulants |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Neuroblastoma | Phase 2 | United States | 12 Aug 2010 | |
High Risk Neuroblastoma | Phase 1 | United States | 01 Jun 2005 | |
Neuroblastoma recurrent | Phase 1 | United States | 01 Jun 2005 |
Phase 2 | 4 | mrcxbeyvfz(quxwauawgx) = dqlyftczrw sevnyizikq (ogrkxjdrhn, ulwkbovniu - jhymeuvcqr) View more | - | 09 Oct 2019 | |||
Phase 2 | 39 | djqcqzvdnj(dzoyhfifbv) = mhokyrwhwn adnvgeqvsb (lmollrggyp, dlamfrfsmj - unkmjbfvpa) View more | - | 13 Aug 2019 | |||
Phase 2 | 31 | ptcliarpws(spclpfwynm) = zapujqcjry ujxwzhtwot (gqexisjmxy, gfhxvebeim - jrmlzeqsah) View more | - | 13 Aug 2019 |